Bellevue Group AG Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001674546
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q4 2025 · 176 positions · Total reported value $5.28B · Top-10 concentration 49.5% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 61.0% · 17 new · 64 cut · 24 exited
Active Share (vs S&P 500): 94.1% · vs QQQ: 96.5% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q1 2026 → Q2 2026): +12.4% · vs SPY -2.4% · Prev Value $4.20B — last quarter positions weighted by this quarter price moves · ranking
In its Q4 2025 13F filing, Bellevue Group AG disclosed 176 equity positions with a combined reported value of $5.28B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 49.5% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.
The largest disclosed positions as of Q4 2025 were RVMD ($398.71M), ARGX ($388.40M), IONS ($379.90M). By sector, the heaviest allocations are Health Care 88.5%, Industrials 1.7%. Versus the prior quarter, allocation shifted toward Other (+3.5pp) and away from Health Care (-3.3pp).
Versus the prior quarter, Bellevue Group AG opened 17 new positions, trimmed 64 and fully exited 24, a turnover rate of 61.0% of positions. The portfolio's overlap with the prior quarter was 75% of names.
The largest new positions opened in Q4 2025 were FOLD ($152.87M), VRDN ($135.64M), NUVL ($104.36M).
Of the 24 positions fully exited versus the prior quarter, the largest were AGIO ($149.11M), AKRO ($113.44M), BHVN ($42.07M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q4 2025)
Fully Exited (vs previous quarter)
- AGIO AGIOS PHARMACEUTICALS INC · prev qtr: $149.11M
- AKRO AKERO THERAPEUTICS INC · prev qtr: $113.44M
- BHVN BIOHAVEN LTD · prev qtr: $42.07M
- HOLX HOLOGIC INC · prev qtr: $16.73M
- MGNX MACROGENICS INC · prev qtr: $16.67M
- BAX BAXTER INTL INC · prev qtr: $1.55M
- BIDU BAIDU INC · prev qtr: $263.54K
- MLTX MOONLAKE IMMUNOTHERAPEUTICS · prev qtr: $251.32K
Insider Transactions (Form 4)
Latest Bellevue Group AG buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Bellevue Group AG files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 148 positions worth $4.75B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Portfolio Structure
- 148 positions · $4.75B reported value (Q2 2026)
- Top 10 holdings = 42.9% of reported value
- Largest position: AMGN (AMGEN INC) at 6.5%
- Average position size: $32.11M
Sector Tilt
- Health Care 92.6%
- Industrials 1.7%
- Information Technology 0.4%
- (classified holdings cover 95% of value)
Quarterly Activity
- Q2 2026: 17 new, 39 added, 64 reduced, 24 exited
- 28 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
Sector Allocation
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
5.01M | $398.71M | 7.56% | Reduce | |
| 2 |
|
461.85K | $388.40M | 7.36% | Reduce | |
| 3 |
|
4.80M | $379.90M | 7.20% | Reduce | |
| 4 |
|
681.12K | $308.79M | 5.85% | Add | |
| 5 |
|
1.70M | $241.58M | 4.58% | Reduce | |
| 6 |
|
2.63M | $189.77M | 3.60% | Add | |
| 7 |
|
322.03K | $182.38M | 3.46% | Reduce | |
| 8 |
|
4.06M | $178.69M | 3.39% | Add | |
| 9 |
|
445.90K | $177.31M | 3.36% | Hold | |
| 10 |
|
1.32M | $165.00M | 3.13% | Reduce | |
| 11 |
|
10.74M | $152.87M | 2.90% | New | |
| 12 |
|
1.56M | $148.71M | 2.82% | Reduce | |
| 13 |
|
4.36M | $135.64M | 2.57% | New | |
| 14 |
|
360.58K | $126.73M | 2.40% | Reduce | |
| 15 |
|
1.04M | $104.36M | 1.98% | New | |
| 16 |
|
410.32K | $101.16M | 1.92% | Add | |
| 17 |
|
3.62M | $98.26M | 1.86% | Add | |
| 18 |
|
2.80M | $97.08M | 1.84% | Hold | |
| 19 |
|
1.04M | $88.92M | 1.69% | Add | |
| 20 |
|
1.70M | $85.99M | 1.63% | New | |
| 21 |
|
766.59K | $73.64M | 1.40% | Add | |
| 22 |
|
8.35M | $70.60M | 1.34% | Hold | |
| 23 |
|
94.54K | $63.96M | 1.21% | Add | |
| 24 |
|
175.17K | $57.83M | 1.10% | Add | |
| 25 |
|
847.40K | $56.24M | 1.07% | Add | |
| 26 |
|
186.70K | $53.07M | 1.01% | Reduce | |
| 27 |
|
265.66K | $51.56M | 0.98% | Reduce | |
| 28 |
|
3.34M | $51.55M | 0.98% | New | |
| 29 |
|
194.63K | $44.56M | 0.84% | Add | |
| 30 |
|
135.40K | $42.10M | 0.80% | Reduce | |
| 31 |
|
161.21K | $38.83M | 0.74% | Reduce | |
| 32 |
|
1.53M | $37.93M | 0.72% | Reduce | |
| 33 |
|
65.08K | $37.71M | 0.71% | Reduce | |
| 34 |
|
887.71K | $36.78M | 0.70% | New | |
| 35 |
|
34.00K | $36.54M | 0.69% | Reduce | |
| 36 |
|
424.51K | $34.82M | 0.66% | Reduce | |
| 37 |
|
3.93M | $34.80M | 0.66% | New | |
| 38 |
|
134.86K | $30.81M | 0.58% | Reduce | |
| 39 |
|
110.01K | $30.28M | 0.57% | Reduce | |
| 40 |
|
261.94K | $29.58M | 0.56% | Add | |
| 41 |
|
126.80K | $26.24M | 0.50% | Add | |
| 42 |
|
5.16M | $25.89M | 0.49% | Hold | |
| 43 |
|
101.70K | $25.78M | 0.49% | Reduce | |
| 44 |
|
1.49M | $25.34M | 0.48% | Reduce | |
| 45 |
|
69.64K | $24.41M | 0.46% | Reduce | |
| 46 |
|
291.96K | $23.93M | 0.45% | Hold | |
| 47 |
|
262.68K | $22.93M | 0.43% | Reduce | |
| 48 |
|
141.47K | $22.09M | 0.42% | Reduce | |
| 49 |
|
238.68K | $21.46M | 0.41% | Reduce | |
| 50 |
|
25.10K | $20.59M | 0.39% | Reduce | |
FAQ
What did Bellevue Group AG buy in 2025-Q4?
In its 2025-Q4 13F filing, Bellevue Group AG reported 176 equity positions worth $5.28B in aggregate; its largest disclosed positions were RVMD ($398.71M), ARGX ($388.40M), IONS ($379.90M).
How large is Bellevue Group AG's portfolio?
Bellevue Group AG reported $5.28B of long equity holdings across 176 positions as of 2025-Q4. Top-10 holdings account for 49.5% of reported value.
What is Bellevue Group AG's investment style?
HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.